Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Bayer Yakuhin to Set Up Committee to Promote Proper Use of Xarelto
April 23, 2012
- TPU Withdraws NDA for Aricept Transdermal Patch: Eisai
April 23, 2012
- Terapia Ranbaxy to Launch Fixed Dose Combination of Olmesartan, Amlodipine in Romania
April 23, 2012
- Daiichi Sankyo Looking to Establish “Base Treatment” Position for Memary
April 23, 2012
- Mylan, Fuso Settle with Kureha in Kremezin Generic Patent Litigation
April 20, 2012
- Kaketsuken and Astellas Enter Sales and Marketing Agreement for Inactivated Polio Combination Vaccine
April 20, 2012
- Meiji Seika Pharma Discontinues Development of Hepatitis C Drug
April 20, 2012
- Nexium No. 1 in Call Frequency in HP Market for 2nd Month in a Row: Rep Track Survey
April 20, 2012
- Bayer Yakuhin Launches Oral Factor Xa Inhibitor Xarelto
April 19, 2012
- Ono’s MS Treatment ONO-4641 Meets Primary Endpoint in PII Study
April 19, 2012
- Novartis Files for Add’l Indication of PAH for Glivec
April 19, 2012
- Takeda to Differentiate New ARB Azilva Stressing Its Strong Hypotensive Effects
April 19, 2012
- JPWA, NPhA Agree to 6-Month Limit on Price Negotiations; Wholesalers’ Resolution to Be Tested for 3rd Time
April 19, 2012
- Teva Pharma Japan Aims at Early Launch of Biosimilars Marketed Overseas in Japan: President Shimada
April 18, 2012
- Dainippon Sumitomo Pharma Files for Supplemental Approval of Surepost in Combination Therapy with Biguanides and with Thiazolidinediones
April 18, 2012
- Hiring of New Pharmacists Sluggish Due to Decreasing Numbers of Applicants, Tough Competition: Major Dispensing Pharmacies
April 18, 2012
- Eisai Launches Insomnia Treatment Lunesta
April 18, 2012
- Daiichi Sankyo Launches Ranmark for Treatment of Bone Lesions Associated with Cancer; AZ to Copromote Product
April 18, 2012
- Eli Lilly Japan Pinning New Hopes on Solanezumab; Will the Introduction of Medicoeconomic Assessments Help?
April 18, 2012
- MediBIC and Kobe University Hospital to Jointly Form Conference on Pharmacogenomics
April 17, 2012
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…